| Breakdown | TTM | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 45.95M | 49.69M | 51.37M | 48.68M | 62.48M | 40.07M |
| Gross Profit | 32.87M | 32.88M | 14.47M | 18.90M | 26.66M | 14.47M |
| EBITDA | 11.40M | 12.29M | 7.75M | 5.89M | 21.53M | 40.07M |
| Net Income | 10.50M | 12.72M | 6.69M | 21.79M | 15.86M | 7.39M |
Balance Sheet | ||||||
| Total Assets | 140.13M | 133.78M | 122.83M | 115.89M | 94.92M | 97.37M |
| Cash, Cash Equivalents and Short-Term Investments | 44.62M | 39.92M | 29.69M | 19.99M | 15.72M | 24.80M |
| Total Debt | 23.00K | 68.00K | 35.00K | 44.00K | 2.03M | 3.45M |
| Total Liabilities | 4.11M | 6.30M | 4.78M | 4.89M | 11.76M | 8.48M |
| Stockholders Equity | 136.03M | 129.96M | 118.05M | 111.00M | 83.16M | 88.89M |
Cash Flow | ||||||
| Free Cash Flow | 4.98M | 9.66M | 10.26M | 6.26M | 14.19M | 12.60M |
| Operating Cash Flow | 5.01M | 10.24M | 10.71M | 6.39M | 15.48M | 12.61M |
| Investing Cash Flow | -513.00K | -553.00K | -457.00K | -131.00K | -1.20M | -5.00K |
| Financing Cash Flow | -9.00K | -9.00K | -9.00K | -1.99M | -23.36M | -5.30M |
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
69 Neutral | $110.24M | 10.62 | 8.04% | ― | -27.32% | -15.12% | |
68 Neutral | $578.07M | 6.62 | 12.52% | ― | -1.52% | 81.35% | |
66 Neutral | $1.32B | 7.96 | 9.82% | ― | 10.13% | -18.11% | |
65 Neutral | $2.17B | 12.19 | 3.79% | 4.94% | 3.15% | 1.96% | |
53 Neutral | $278.30M | 48.32 | 0.95% | ― | -0.58% | ― |
On January 26, 2026, Amrep’s board of directors approved changes to its governance structure, effective January 27, 2026, by expanding the board from four to five members and reallocating directors among its classified board structure. The number of Class III directors was increased from one to two, with Mr. McNaney designated as a Class III director, and the company’s bylaws were amended so that the board will now formally consist of five directors, signaling an expansion of board oversight and potential for broader strategic input at the governance level.
The most recent analyst rating on (AXR) stock is a Hold with a $21.50 price target. To see the full list of analyst forecasts on Amrep stock, see the AXR Stock Forecast page.